Download PDF
Thromb Haemost 1991; 66(06): 684-693
DOI: 10.1055/s-0038-1646486
Original Article
Schattauer GmbH Stuttgart

Enhancement of Clot Lysis In Vitro and In Vivo with a Bispecific Monoclonal Antibody Directed against Human Fibrin and against Urokinase-Type Plasminogen Activator

Tomofumi Kurokawa
*   The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium
**   Biotechnology Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, Japan
,
Susumu Iwasa
**   Biotechnology Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, Japan
,
Atsushi Kakinuma
**   Biotechnology Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, Japan
,
Jean-Marie Stassen
*   The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium
,
H Roger Lijnen
*   The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium
,
Desire Collen
*   The Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 13 January 1991

Accepted 18 June 1991

Publication Date:
26 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A hybrid hybridoma (FU1-74), secreting a bispecific monoclonal antibody (bs mAb), was obtained by fusion of a murine hybridoma secreting a monoclonal antibody (mAb) specific for human fibrin with a murine hybridoma secreting a mAb against urokinase-type plasminogen activator (u-PA). The bs mAb (MA-FU1-74), purified to homogeneity from mouse ascitic fluid, migrated as a single band with apparent M r 150,000 on non-reduced SDS-PAGE and had an affinity for both human fibrin (K a = 2 × 107 M–1) and for u-PA (K a = 108 M–1) comparable to that of the mAbs obtained from the respective parental hybridomas. MA-FU1-74 did not influence the enzymatic activity of two-chain u-PA (tcu-PA) towards plasminogen or towards a chromogenic substrate. The complex of MA-FU1-74 with recombinant single chain u-PA (rscu-PA) or with tcu-PA (urokinase) enhanced the fibrinolytic potency of the plasminogen activator towards clotted human plasma 20-fold and 5-fold, respectively.

In a hamster pulmonary embolism model, the rscu-PA/MA-FU1-74 complex had a 13- to 17-fold increased thrombolytic potency (percent lysis per mg/kg u-PA administered) relative to that of rscu-PA. The specific thrombolytic activity (percent lysis per εg/ml steady state plasma level of u-PA antigen) of the complex was, however, not significantly different from that of rscu-PA. The complex of rscu-PA with the parental anti-u-PA mAb (MA-UK1-3) had only a 2-fold enhanced thrombolytic potency relative to that of rscu-PA and had a 5-fold decreased specific thrombolytic activity. The plasma clearance rates of the complexes of rscu-PA with both MA-FU1-74 and MA-UK1-3 were about 10-fold lower than that of rscu-PA. In a rabbit jugular vein thrombosis model, the rscu-PA/MA-FU1-74 complex had a 4-fold enhanced thrombolytic potency, an unchanged specific thrombolytic activity and 20-fold reduced plasma clearance. In both animal models, the rscu-PA/MA-FUl-74 complex did not cause more extensive systemic activation of the fibrinolytic system than rscu-PA.

It is concluded that the bispecific anti-fibrin/anti-u-PA mAb MA-FU1-74 targets u-PA to the fibrin clot, resulting in a significantly enhanced thrombolytic potency of the plasminogen activator.

 

  • References

  • 1 Guenzler WA, Steffens GJ, Oetting F, Kim SMA, Frankus E, Flohe L. The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain. Hoppe Seyler's Z Physiol Chem 1982; 363: 1155-65
    PubMedGoogle Scholar
  • 2 Holmes WE, Pennica D, Blaber M, Rey MW, Guenzler WA, Steffens GJ, Heyneker HL. Cloning and expression of the gene for prourokinase in Escherichia coli. . Biotechnology 1985; 3: 923-9
    CrossrefPubMedGoogle Scholar
  • 3 Lijnen HR, Van Hoef B, De Cock F, Collen D. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. Blood 1989; 73: 1864-72
    PubMedGoogle Scholar
  • 4 Lijnen HR, Van Hoef B, Nelles L, Collen D. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser 740 → Ala) and plasmin resistant scu-PA (Lys 158 → Glu). J Biol Chem 1990; 265: 5232-6
    PubMedGoogle Scholar
  • 5 Guenzler WA, Steffens GJ, Oetting F, Buse G, Flohe L. Structural relationship between human high and low molecular mass urokinase. Hoppe Seyler's Z Physiol Chem 1982; 363: 133-41
    PubMedGoogle Scholar
  • 6 Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest 1984; 73: 1731-9
    CrossrefPubMedGoogle Scholar
  • 7 Zamarron C, Lijnen HR, Van Hoef B, Collen D. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology. Thromb Haemostas 1984; 52: 19-23
    PubMedGoogle Scholar
  • 8 Van de Werf F, Nobuhara M, Collen D. Coronary thrombolysis with human single-chain urokinase-type plasminogen activator (prourokinase) in patients with acute myocardial infarction. Ann Intern Med 1986; 104: 345-8
    CrossrefPubMedGoogle Scholar
  • 9 PRIMI Trial Study Group Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989; 1: 863-8
    PubMedGoogle Scholar
  • 10 Collen D, Stump DC, Gold HK. Thrombolytic therapy. Annu Rev Med 1988; 39: 405-23
    CrossrefPubMedGoogle Scholar
  • 11 Collen D, De Cock F, Lijnen HR. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys. Thromb Haemostas 1984; 52: 24-6
    PubMedGoogle Scholar
  • 12 Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. J Biol Chem 1987; 262: 10855-62
    PubMedGoogle Scholar
  • 13 De Vries C, Veerman H, Blasi F, Pannekoek H. Artificial exon shuffling between tissue-type plasminogen activator (t-PA) and urokinase (u-PA): a comparative study on the fibrinolytic properties of t-PA/u-PA hybrid proteins. Biochemistry 1988; 27: 2565-72
    CrossrefPubMedGoogle Scholar
  • 14 Bode C, Matsueda G, Hui KY, Haber E. Antibody-directed urokinase: A specific fibrinolytic agent. Science 1985; 229: 765-7
    CrossrefPubMedGoogle Scholar
  • 15 Bode C, Runge MS, Newell JB, Matsueda GR, Haber E. Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin. J Biol Chem 1987; 262: 10819-23
    PubMedGoogle Scholar
  • 16 Dewerchin M, Lijnen HR, Van Hoef B, De Cock F, Collen D. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin. Eur J Biochem 1989; 185: 141-9
    CrossrefPubMedGoogle Scholar
  • 17 Collen D, Dewerchin M, Stassen JM, Kieckens L, Lijnen HR. Thrombolytic and pharmacokinetic properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin. Fibrinolysis 1989; 3: 197-202
    PubMedGoogle Scholar
  • 18 Charpie JR, Runge MS, Matsueda GR, Collen D, Haber E. Enhancement of fibrinolysis by single chain urokinase (scu-PA) with a bifunctional antibody having both fibrin and scu-PA specificities. Clin Res 1988; 36: 436A (Abstract)
    PubMedGoogle Scholar
  • 19 Bode C, Runge MS, Branscomb EE, Newell JB, Matsueda GR, Haber E. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator. J Biol Chem 1989; 264: 944-8
    PubMedGoogle Scholar
  • 20 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-6
    CrossrefPubMedGoogle Scholar
  • 21 Blombôck B, Blombôck M. Purification of human and bovine fibrinogen. Arkiv Kemi 1956; 10: 415-43
    PubMedGoogle Scholar
  • 22 Haverkate F, Timan G. Protective effect of calcium in the plasmin degradation of fibrinogen and fibrin fragments D. Thromb Res 1977; 10: 803-12
    CrossrefPubMedGoogle Scholar
  • 23 Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983; 222: 1129-31
    CrossrefPubMedGoogle Scholar
  • 24 Kurokawa T, Iwasa S, Kakinuma A. Enhanced fibrinolysis by a bispecific monoclonal antibody reactive to fibrin and tissue plasminogen activator. Biotechnology 1989; 7: 1163-7
    CrossrefPubMedGoogle Scholar
  • 25 Jentoft N, Dearborn DG. Protein labeling by reductive alkylation. Meth Enzymol 1983; 91: 570-9
    PubMedGoogle Scholar
  • 26 Hofmann K, Finn FM, Kiso Y. Avidin/biotin affinity columns. General methods for attaching biotin to peptides and proteins. J Am Chem Soc 1978; 100: 3585-90
    CrossrefPubMedGoogle Scholar
  • 27 Marchalonis JJ. An enzymic method for the trace iodination of immunoglobulins and other proteins. Biochem J 1969; 113: 299-305
    CrossrefPubMedGoogle Scholar
  • 28 Vermylen C, De Vreker RA, Verstraete M. A rapid enzymatic method for assay of fibrinogen: the fibrin polymerization test (F.P.T.). Clin Chim Acta 1983; 8: 418-24
    PubMedGoogle Scholar
  • 29 Edy J, Collen D, Verstraete M. Quantitation of the plasma protease inhibitor antiplasmin with the chromogenic substrate S-2251. In: Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 3.. Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (eds) Raven Press, New York: 1978. pp 315-22
    Google Scholar
  • 30 Darras V, Thienpont M, Stump D, Collen D. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb Haemostas 1986; 56: 411-4
    PubMedGoogle Scholar
  • 31 Gefter ML, Margulies DH, Scharff MD. A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet 1977; 3: 231-6
    CrossrefPubMedGoogle Scholar
  • 32 Karawajew L, Micheel B, Behrsing O, Gaestel M. Bispecific antibody-producing hybrid hybridomas selected by a fluorescence activated cell sorter. J Immunol Methods 1987; 96: 265-70
    CrossrefPubMedGoogle Scholar
  • 33 Iwasa S, Konishi E, Kondo K, Suzuki T, Akaza H, Niijima T. Selective cytotoxicity of drug-monoclonal antibody conjugates against murine bladder tumor cells. Chem Pharm Bull Tokyo 1987; 35: 1128-37
    CrossrefPubMedGoogle Scholar
  • 34 Staerz UD, Bevan MJ. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci USA 1986; 83: 1453-7
    CrossrefPubMedGoogle Scholar
  • 35 Tada H, Toyoda Y, Iwasa S. Bispecific antibody-producing hybrid hybridoma and its use in one-step immunoassays for human lymphotoxin. Hybridoma 1989; 8: 73-83
    CrossrefPubMedGoogle Scholar
  • 36 Frankel ME, Gerhard W. The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay. An analysis of the interaction between hybridoma proteins and influenza virus. Mol Immunol 1979; 16: 101-6
    CrossrefPubMedGoogle Scholar
  • 37 Declerck PJ, Lijnen HR, Verstreken M, Moreau H, Collen D. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma. Blood 1990; 75: 1794-800
    PubMedGoogle Scholar
  • 38 Stassen JM, Vanlinthout I, Lijnen HR, Collen D. A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents. Fibrinolysis 1990; 4 (Suppl 2) 15-21
    PubMedGoogle Scholar
  • 39 Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest 1983; 71: 368-76
    CrossrefPubMedGoogle Scholar
  • 40 Gibaldi M, Perrier D. Pharmacokinetics. Marcel Dekker, New York: 1983. pp 45-111
    Google Scholar
  • 41 Bode C, Runge MS, Branscomb EE, Newell JB, Matsueda GR, Haber E. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator. J Biol Chem 1989; 264: 944-8
    PubMedGoogle Scholar
  • 42 Branscomb EE, Runge MS, Savard CE, Adams KM, Matsueda GR, Haber E. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator. Thromb Haemostas 1990; 64: 260-6
    PubMedGoogle Scholar